---
schema_version: "secwatch.filing_event.v1"
accession: "0001847903-23-000187"
form_type: "8-K"
ticker: "CNTA"
cik: "0001847903"
company_name: "Centessa Pharmaceuticals plc"
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T05:28:40.524962+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Centessa Q3 2023 net loss $38.6M; cash $281.3M, SerpinPC data at ASH

## Summary
- Cash and investments $281.3M as of Sep 30, 2023; expected to fund operations into 2026.
- Net loss of $38.6M vs $53.9M in Q3 2022; R&D expense $28.2M, down 23% YoY.
- SerpinPC Phase 2a Part 5 data accepted for ASH poster Dec 10; PRESent-2 and PRESent-3 registrational studies ongoing.
- ORX750 (OX2R agonist) preclinical data support best-in-class profile for narcolepsy; IND-enabling studies underway, clinical proof-of-concept data planned for 2024.
- LockBody platform: LB101 (PD-L1xCD47) Phase 1/2a ongoing; LB206 (PD-L1xCD3) development candidate selected in August.

## SEC filing metadata
- accession: 0001847903-23-000187
- form_type: 8-K
- ticker: CNTA
- cik: 0001847903
- company_name: Centessa Pharmaceuticals plc
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847903/000184790323000187/0001847903-23-000187-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847903/000184790323000187/cnta-20231113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001847903-23-000187
- JSON: https://secwatch.observer/filing/0001847903-23-000187.json
- Plain text: https://secwatch.observer/filing/0001847903-23-000187.txt

## Key facts
- Earnings Releases
  Centessa Pharmaceuticals plc reported the third quarter ended September 30, 2023 results: net income $38.6 million.
  - Period: the third quarter ended September 30, 2023
  - Net income: $38.6 million
  - Result: reported results
  source text: Centessa Pharmaceuticals plc (the “Company”) announced its financial results for the quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1847903/000184790323000187/0001847903-23-000187-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.